Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018102591) BIOMARKER TEST AND METHOD FOR ASSESSING MUCOSAL HEALING IN RESPONSE TO TREATMENT OF ULCERATIVE COLITIS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/102591 International Application No.: PCT/US2017/064029
Publication Date: 07.06.2018 International Filing Date: 30.11.2017
IPC:
G01N 33/68 (2006.01) ,G01N 33/74 (2006.01) ,G01N 33/564 (2006.01) ,G06F 19/00 (2018.01)
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68
involving proteins, peptides or amino acids
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
74
involving hormones
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
564
for pre-existing immune complex or autoimmune disease
G PHYSICS
06
COMPUTING; CALCULATING; COUNTING
F
ELECTRIC DIGITAL DATA PROCESSING
19
Digital computing or data processing equipment or methods, specially adapted for specific applications
Applicants:
KEPLER DIAGNOSTICS, INC. [US/US]; 4685 Runway Street Suite K Simi Valley, California 93063, US
KATHOLIEKE UNIVERSITEIT LEUVEN [BE/BE]; Katholieke Universiteit Leuven KU Leuven Research & Development Waaistraat 6, box 5105 3000 Leuven, BE
Inventors:
DUKLER, Avinoam; US
RINGOLD, Randy; US
VERMEIRE, Severine; BE
DE BRUYN, Magali; BE
OPDENAKKER, Ghislain; BE
Agent:
LAGOBI, Karim; US
Priority Data:
62/429,06901.12.2016US
62/457,13909.02.2017US
Title (EN) BIOMARKER TEST AND METHOD FOR ASSESSING MUCOSAL HEALING IN RESPONSE TO TREATMENT OF ULCERATIVE COLITIS
(FR) ESSAI DE BIOMARQUEUR ET PROCÉDÉ D’ÉVALUATION DE CICATRISATION DES MUQUEUSES EN RÉPONSE AU TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE
Abstract:
(EN) Mucosal healing is an indication to the disease activity level in patients affected by inflammatory bowel diseases, and it is thus far mainly monitored by endoscopy. Instead or in addition to endoscopy, the invention provides blood test using biomarkers and an index that allows a practitioner to assess the status of mucosal healing, to change or adapt dosage of treatment and to predict which patient will become responder versus non-responder to treatment as assessed by endoscopy. While none of neutrophils cell count, c-reactive protein (CRP), Human type of Cathelicidin (LL-37), or Chitinase 3-like 1 (CHI3L1) alone is able to provide an assessment means of mucosal healing, the invention provides a novel combination of the levels of these biomarkers to assess the level of mucosal healing in relation to endoscopic healing.
(FR) La cicatrisation des muqueuses est une indication du niveau d’activité de la maladie chez des patients affectés par des maladies inflammatoires intestinales, et celle-ci est ainsi, à ce jour, principalement surveillée par endoscopie. Au lieu ou en plus de l’endoscopie, l’invention concerne un test sanguin utilisant des biomarqueurs et un indice qui permet à un praticien d’évaluer l’état de cicatrisation d’une muqueuse, de modifier ou adapter la dose de traitement et de prédire quel patient sera répondeur ou non répondeur à un traitement comme évalué par endoscopie. Bien qu’aucun parmi le nombre de cellules neutrophiles, la protéine C réactive (CRP), le type humain de cathélicidine (LL-37), ou la chitinase 3-like 1 (CHI3L1) ne soit seul capable de constituer un moyen d’évaluation de la cicatrisation de la muqueuse, l’invention concerne une nouvelle combinaison des taux de ces biomarqueurs pour évaluer le taux de cicatrisation de muqueuse par rapport à la cicatrisation endoscopique.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)